<DOC>
	<DOC>NCT02491905</DOC>
	<brief_summary>This study evaluates the safety and efficacy of HL tablet on reducing hepatic fat in non-alcoholic fatty liver disease patients. The patients are allocated to three groups; low dose, high dose, and placebo control group.</brief_summary>
	<brief_title>Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1. Age between 19 and 75 2. Nonalcoholic fatty liver disease patient Diagnosed by abdomen ultrasonic examination Nondrinker (alcohol intake per week : femaleunder 140g, maleunder 210g) 3. ALT or AST higher than normal range (not over 4 times normal range) 4. Voluntary agreement and enrollment 1. The ratio of AST/ALT over 2 2. Type I diabetes mellitus patient 3. Any dysfunction of liver besides nonalcoholic fatty liver disease 4. Alcoholic fatty liver disease patient or heavy drinker 5. Prior treatment with any medicine which affects the treatment of nonalcoholic fatty liver disease within 3 months 6. Patient taking any product which affects the BMI or hyperlipidemia 7. Any dyscrasia that investigator considers not to appropriate for this study 8. Bariatric surgery within 6 months 9. Any disease which is able to change the distribution of cytokines 10. Any treatment that affects liver functions within 1 month 11. Participation in other clinical trials within 3 months 12. Person who can not use MRS 13. Pregnancy or breastfeeding 14. Fertile women who do not use contraception 15. Sensitive to the investigational product 16. Any conditions that the investigator considers not to appropriate for this study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>